Conference Reports for NATAP

64rd Annual Meeting of the American Association for the Study of Liver Diseases Washington, DC Nov 1-5 2013 Back

Boehringer Ingelheim       AASLD: Rapid and Consistent Virologic Responses in a Phase 2 Trial of a New All-Oral Combination of Faldaprevir, Deleobuvir and PPI-668, with and without Ribavirin, in Patients with HCV Genotype-1a Infection - (11/04/13)   AASLD: STARTVerso4 PHASE III TRIAL OF FALDAPREVIR PLUS PEGYLATED INTERFERON α-2a AND RIBAVIRIN IN PATIENTS WITH HIV AND HCV GENOTYPE-1 CO-INFECTION - (11/10/13)   AASLD: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE III TRIAL OF FALDAPREVIR IN COMBINATION WITH PEGYLATED INTERFERON α-2a AND RIBAVIRIN IN TREATMENT-EXPERIENCED PATIENTS WITH CHRONIC HCV GENOTYPE-1 INFECTION - (11/10/13)   AASLD: STARTVerso4 PHASE III TRIAL OF FALDAPREVIR PLUS PEGYLATED INTERFERON α-2a AND RIBAVIRIN IN PATIENTS WITH HIV AND HCV GENOTYPE-1 CO-INFECTION - (11/11/13)   AASLD: MASS BALANCE, METABOLIC PROFILE, AND THE ROLE OF HEPATIC AND BACTERIAL ENZYMES IN THE METABOLISM OF THE HCV POLYMERASE INHIBITOR, DELEOBUVIR - (11/11/13)   AASLD: PHARMACOKINETIC INTERACTIONS OF FALDAPREVIR AND DELEOBUVIR AND THEIR INDIVIDUAL AND COMBINED EFFECT ON SELECTED CYTOCHROME P450 PROBE SUBSTRATES IN PATIENTS INFECTED WITH GENOTYPE-1 HCV - (11/11/13)   AASLD: INTERFERON-FREE TREATMENT WITH FALDAPREVIR, DELEOBUVIR, AND RIBAVIRIN IN SOUND-C3: 95% SVR12 IN HCV GENOTYPE-1b - (11/11/13)   AASLD: A POOLED ANALYSIS OF TWO RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE III TRIALS (STARTVerso1 AND 2) OF FALDAPREVIR PLUS PEGYLATED INTERFERON a-2a AND RIBAVIRIN IN TREATMENT-NAIVE PATIENTS WITH CHRONIC HEPATITIS C GENOTYPE-1 INFECTIONBACKGROUND - (11/10/13)   AASLD: SUBGROUP ANALYSES AND BASELINE PREDICTORS OF RESPONSE WITH FALDAPREVIR PLUS PEGYLATED INTERFERON a-2a AND RIBAVIRIN IN TREATMENT-NAIVE PATIENTS WITH CHRONIC HEPATITIS C GENOTYPE-1 INFECTION: A POOLED ANALYSIS OF STARTVerso1 AND 2 - (11/10/13)   AASLD: EFFECT OF STEADY-STATE FALDAPREVIR ON THE PHARMACOKINETICS OF STEADY-STATE METHADONE AND BUPRENORPHINE/NALOXONE IN SUBJECTS ON STABLE ADDICTION MANAGEMENT THERAPY - (11/10/13)   AASLD: EFFECT OF MULTIPLE ORAL DOSES OF FALDAPREVIR ON THE MULTIPLE DOSE PHARMACOKINETICS OF A COMBINATION ORAL TABLET OF ETHINYLESTRADIOL AND LEVONORGESTREL IN HEALTHY PREMENOPAUSAL FEMALE VOLUNTEERS - (11/10/13)   AASLD: PHARMACOKINETICS, SAFETY, AND TOLERABILITY OF FALDAPREVIR IN PATIENTS WITH DIFFERENT LEVELS OF RENAL IMPAIRMENT - (11/10/13)   AASLD: Boehringer Ingelheim's interferon-free hepatitis C treatment portfolio strengthened by promising Phase II data - (11/02/13) press release   AASLD: Phase III data show Boehringer Ingelheim's faldaprevir* was highly effective in a broad range of patients with genotype-1 hepatitis C - (11/02/13) - press release   64rd Annual Meeting of the American Association for the Study of Liver Diseases Washington, DC Nov 1-5 2013